NextCure and Avere Strengthen Oral IL-23 Development
SAN FRANCISCO, July 14, 2026 NextCure and privately held Avere Therapeutics have entered into a definitive all-stock merger agreement...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SAN FRANCISCO, July 14, 2026 NextCure and privately held Avere Therapeutics have entered into a definitive all-stock merger agreement...
LA JOLLA, Calif., June 24, 2026 CalciMedica, Inc. (Nasdaq: CALC) announced a private placement financing of up to approximately...
NEW HAVEN, Conn. & SAN DIEGO, Calif., June 2, 2026 Rallybio Corporation and Avenzo Therapeutics announced a definitive merger...
Rutherford, New Jersey | December 30, 2025 — Glucotrack, Inc., a medical technology company focused on diabetes care innovation,...
December 19, 2025 | Pittsburgh, Pennsylvania and Toronto, Ontario — Sharp Therapeutics Corp. has announced an updated non-brokered private...
Vancouver, British Columbia, December 18, 2025 — Restart Life Sciences Corp., a Canadian-based life sciences company, has successfully closed...
VANCOUVER, British Columbia — December 5, 2025 — Restart Life Sciences Corp. announced the successful closing of the first...
Sydney, Australia, December 3, 2025 — Kazia Therapeutics has announced the pricing of a US $50 million private placement...
PARIS, October 17, 2025 AB Science S.A., a biopharmaceutical company focused on discovering, developing, and marketing protein kinase inhibitors,...
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing therapies for neurodegenerative diseases, has entered into a...
